Medavante-ProPhase

What Medavante-ProPhase does

Medavante-ProPhase is a privately held clinical trial technology company founded in 2000 and headquartered in Hampton, United States, with a workforce of 101–250 employees. Per firmographic data, the company provides technology-enabled signal detection solutions designed to support clinical trials of treatments targeting nervous system disorders, operating in the specialized neuroscience clinical research technology segment of the broader clinical trial services market. Its offering focuses on detecting and measuring clinically meaningful signals in CNS therapeutic development, where regulatory-grade endpoint sensitivity and rater consistency are critical value drivers.

The detailed source material (sourced from clario.com) documents an adjacent clinical trial endpoint technology platform with integrated solutions across multiple therapeutic-area modalities: cardiac safety (ECG, arrhythmia analysis, blood pressure, Phase I/TQT assessment), electronic clinical outcome assessments (eCOA) including a neuroscience specialization, medical imaging core lab services with AI-powered redaction, precision motion wearables using the Opal V2R research-grade sensor, respiratory solutions including virtual home spirometry and AI-enabled spirometry insights, and clinical adjudication services. The platform is supported by trial enablement software (eligibility, reporting and analytics, source document manager) and offers dedicated AI capabilities. Whether Medavante-ProPhase operates as a distinct CNS-focused vendor, a subsidiary, or a brand within this broader platform cannot be conclusively determined from the supplied sources.

No revenue, ownership, investor, pricing, customer-concentration, or management-team data is disclosed for Medavante-ProPhase in the supplied sources, and no explicit operating geographies, customer logos, distribution channels, marketing channels, awards, patents, or partnership details are documented. Compliance certifications referenced in the source material (ISO 27001, ISO 42001, 21 CFR Part 11, GDPR) apply to the broader clinical trial endpoint technology platform rather than to Medavante-ProPhase specifically.

Name

Medavante-ProPhase

Website

https://medavante-prophase.com

Company type

Private

Founded year

2000

Headcount range

101–250 employees

Short description

Medavante-ProPhase is a privately held clinical trial technology company providing technology-enabled signal detection solutions for clinical trials of treatments targeting nervous system disorders. Founded in 2000 in Hampton, United States, with 101–250 employees.

Ownership category

akta.pro rank

Product category

Clinical Trial Services for CNS Disorders

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

akta.pro secondary industries

Clinical Trial Management Systems (CTMS) (HLACAOAD), Signal Detection & Safety Analytics (Epidemiology/RWE) (HLAGALAC)

Keywords

• Clinical trial services
• Signal detection solutions
• Neuroscience clinical research
• CNS clinical assessments
• Technology-enabled trials

Headquarters

HQ city

Hampton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Medavante-ProPhase provides technology-enabled signal detection solutions for clinical trials of treatments targeting nervous system disorders. The company supports sponsors conducting central nervous system (CNS) studies with technology-driven tools and services that capture and analyze clinical outcome data in trials for neurological and psychiatric indications.

Product overview

Clario is a comprehensive clinical trial endpoint technology and evidence generation platform offering integrated solutions across multiple modalities. The platform provides five core product areas: Cardiac Safety (ECG, arrhythmia analysis, blood pressure), eCOA (electronic clinical outcome assessments including neuroscience and oncology specialties), Medical Imaging (core lab services with AI-powered redaction), Precision Motion (wearable sensors for mobility endpoints), and Respiratory Solutions (spirometry and pulmonary function testing). These solutions are supported by Trial Enablement software for eligibility, analytics, and document management. The company also offers dedicated AI technology and hybrid/decentralized trial capabilities. Clario has 50+ years of experience, has supported over 30,000 clinical trials, and was acquired by Thermo Fisher Scientific in 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• Technology-Enabled Signal Detection Solutions

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• WCG: Clinical trial enablement provider offering IRB, technology, and site support services. Comparable through its focus on clinical trial operations and endpoint quality infrastructure.
• IQVIA: Largest global CRO and clinical technology provider with eCOA, imaging, and decentralized trial capabilities. Competes broadly across all endpoint modalities but does not specialize in CNS signal detection.
• Parexel: Global full-service CRO with strength in CNS and a broad technology ecosystem (post Roivant partnership). Comparable as an incumbent across CNS trials and eClinical services.
• Medidata (Dassault Systèmes): Major clinical trial technology platform (Rave EDC, eCOA, imaging) serving most large sponsors. Comparable as a broad eClinical incumbent with overlapping eCOA functionality.
• Veeva Systems: Cloud-based life sciences software platform with Vault CDMS, Vault EDC, and ePRO capabilities. Comparable as a clinical trial software incumbent competing for sponsor technology spend.

Direct peers

• Clario: Clinical trial endpoint technology platform offering cardiac, eCOA, imaging, motion, and respiratory solutions with strong CNS capability. Closely aligns with Medavante-ProPhase's multi-modality endpoint scope and neuroscience specialization.
• Signant Health: Specialty eCOA and CNS clinical outcome assessment provider formed from the merger of CRF Health and Bracket. Directly comparable to Medavante-ProPhase on electronic clinical outcomes in neuroscience and signal detection in CNS trials.
• Worldwide Clinical Trials: Mid-sized CRO with a strong CNS/neuroscience focus across early to late-phase trials. Comparable through its neuroscience therapeutic specialization and operational expertise in CNS endpoint quality.

Emerging players

• Cogstate: Cognitive assessment and eCOA technology provider focused on CNS endpoints (e.g., Alzheimer's, oncology-related cognitive impairment). Comparable via digital CNS endpoint delivery into clinical trials.

Others

• ERT (now part of Clario): Historical clinical outcomes technology provider in cardiac safety, respiratory, and eCOA; merged into Clario. Comparable via overlapping endpoint technology portfolio and shared CNS trial heritage with Medavante.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/follow
• LinkedInlinkedin.com/company/medavante-prophase

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medavante-ProPhase